RELATED STUDY
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Key Findings: Most evidence points toward an involvement of CB1 and also CB2 receptors, especially with regard to immune cell recruitment. Further research in this direction, preferably on human IBD material, such as explants, cultured biopsies, etc. is highly warranted.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Austria, Germany
Year of Pub: 2017
Cannabinoids Studied: Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified), Pharma THC, Pharma THC:CBD
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype I, Chemotype II
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, PPAR - Alpha, GPCR, TRPs, PPARs
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Citation: Hasenoehrl C, et al. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?. Expert Rev Gastroenterol Hepatol. 2017; 11:329-337. doi: 10.1080/17474124.2017.1292851
Authors: Hasenoehrl C, Storr M, Schicho R
